<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[36, 39] efficacy and safety<br>[156, 159] response rate.<br>[160, 162] response rates<br>[182, 186] time to treatment failure<br>[199, 202] time to progression<br>[215, 217] survival time<br>[233, 235] toxicity profile<br>[260, 272] feasible and effective for advanced non-small cell lung cancer.<br>[283, 289] response rate and survival data.<br></td>
<td width=33%>
[36, 39] efficacy and safety<br>[156, 159] response rate.<br>[160, 162] response rates<br>[182, 186] time to treatment failure<br>[199, 202] time to progression<br>[215, 217] survival time<br>[233, 235] toxicity profile<br>[260, 272] feasible and effective for advanced non-small cell lung cancer.<br>[283, 289] response rate and survival data.<br></td>
<td width=33%>
[19, 27] advanced non-small cell lung cancer.<br>[36, 39] efficacy and safety<br>[156, 159] response rate.<br>[160, 162] response rates<br>[181, 186] Median time to treatment failure<br>[198, 202] Median time to progression<br>[214, 217] Median survival time<br>[233, 242] toxicity profile was relatively mild and did not differ<br>[256, 272] was determined to be feasible and effective for advanced non-small cell lung cancer.<br>[282, 289] higher response rate and survival data.<br></td>
</tr>
